Riskpilot← Back to searchSign inGet full accessCD Läkarkonsult AB
ABActiveOrg 5568900244Järnåkravägen 21 AGeneral medical practice activities · NACE 8621Est. 20120 employees
Revenue 2024
SEK 1,4M
-38% vs 2023
EBITDA margin
18.9%
-75% vs 2023
Equity ratio
44.4%
Financial strength
Net profit 2024
SEK -712K
-10244% vs 2023
| Revenue | SEK 1,4M | -38% |
| EBITDA | SEK 267K | -75% |
| Net profit | SEK -712K | -10244% |
| Total assets | SEK 5,8M | -19% |
| Equity | SEK 2,6M | -30% |
| Employees | 0 | — |
Legal name
CD Läkarkonsult AB
Org number
5568900244
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
4 april 2012
Share capital
SEK 100 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Föremålet för bolagets verksamhet är att bedriva sjukvårds- verksamhet samt äga och förvalta fastigheter och därmed förenlig verksamhet.
Address
Järnåkravägen 21 A
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 4 275 | 3 236 | 2 483 | 2 297 | 1 413 |
| Staff expenses | — | — | −1 109 | −975 | −908 |
| EBITDA | 2 827 | 1 782 | 977 | 1 081 | 267 |
| Depreciation & amort. | −82 | −89 | −89 | −89 | −7 |
| EBIT | 2 745 | 1 693 | 887 | 992 | 259 |
| Net financials | −20 | −5 | −3 | −835 | −1 155 |
| Profit before tax | 2 222 | 1 407 | 861 | 247 | −569 |
| Tax | −488 | −298 | −208 | −240 | −143 |
| Net profit | 1 734 | 1 109 | 653 | 7 | −712 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 8 074 | 9 910 | 9 906 | 7 073 | 5 761 |
| Equity | 4 149 | 4 559 | 4 042 | 3 659 | 2 557 |
| Long-term debt | 157 | 0 | — | — | — |
| Short-term debt | 1 187 | 2 487 | 2 977 | 618 | 734 |
| Total debt | 1 344 | 2 487 | 2 977 | 618 | 734 |
EBITDA margin
18.9%
This company
15.8%
Market median
+20% vs market
20202024
Equity ratio
44.4%
This company
38.2%
Market median
+16% vs market
20202024
Return on equity
-27.8%
This company
18.4%
Market median
-251% vs market
20202024
Net profit margin
-50.4%
This company
8.1%
Market median
-722% vs market
20202024
Asset turnover
0.25×
This company
1.12×
Market median
-78% vs market
20202024
Debt / equity
1.25×
This company
0.62×
Market median
-102% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2022 | |
| Deputy Board Member | 2025 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
CD Läkarkonsult AB 
Delaziz Invest ABBoard members of CD Läkarkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Charlotte Mahsama Delavaran Shiraz | Board of Directors | 0 companies |
| Assall Fatima Delavaran | Deputy Board Member | 0 companies |